- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07584122
Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro
Bringing PrEP to Underserved Communities in Rio de Janeiro: the PrEPOUT Rio Study
This study aims to improve access to HIV prevention using pre-exposure prophylaxis (PrEP) among underserved populations in Rio de Janeiro, including gay and bisexual men, transgender women, and sex workers. Despite the proven effectiveness of PrEP, many people at higher risk of HIV face barriers to accessing and continuing this prevention method, especially those living in socially and economically vulnerable communities.
The study will evaluate whether offering PrEP directly in community-based settings-such as non-governmental organizations, mobile health units, and through telehealth and digital tools-can increase its uptake and continued use. Participants who test negative for HIV will be offered daily oral PrEP, along with counseling and follow-up support. Those who test positive will be referred for appropriate treatment.
The main hypothesis is that delivering PrEP in community settings, combined with supportive strategies like mobile health interventions, will be feasible, acceptable, and more effective in reaching and engaging vulnerable populations, ultimately helping to reduce new HIV infections.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The PrEPOUT Rio Study is designed to evaluate the implementation of community-based strategies to expand access to and engagement with oral pre-exposure prophylaxis (PrEP) for HIV prevention among underserved populations in Rio de Janeiro and the metropolitan area, including Nova Iguaçu. The study focuses on populations disproportionately affected by HIV, such as gay, bisexual, and other men who have sex with men (MSM), transgender women, other sexual and gender minorities, and sex workers.
The study will be conducted in three phases. The formative phase will use qualitative methods, including focus group discussions with key stakeholders and members of the target population, to identify barriers and facilitators to PrEP uptake and to inform the adaptation of community-based delivery strategies.
In the implementation phase, PrEP will be offered in non-traditional settings, including community-based organizations and mobile health units, aiming to reduce structural and social barriers to access. Trained healthcare staff will provide on-site HIV testing, counseling, and PrEP initiation. Participants who test HIV-negative will be offered daily oral PrEP, while those diagnosed with HIV will be promptly referred for treatment within the public health system. The study will also incorporate supportive strategies such as telehealth consultations and mobile health (mHealth) interventions to enhance adherence, retention, and engagement in care.
The evaluation phase will include both quantitative and qualitative approaches to assess implementation and clinical outcomes. Quantitative data will be collected through structured questionnaires and clinical assessments to evaluate PrEP uptake, adherence, persistence, and HIV incidence, as well as the acceptability and feasibility of the intervention. Qualitative data from follow-up focus groups will provide insights into participants' experiences and perceptions of community-based PrEP delivery models.
The primary objective is to assess the feasibility and acceptability of delivering PrEP in community-based settings. Secondary objectives include evaluating engagement with telehealth and digital tools, identifying barriers and facilitators to PrEP use, and assessing HIV and sexually transmitted infection (STI) outcomes in the study population. The findings are expected to inform scalable strategies to improve equitable access to HIV prevention services in settings with significant social and structural inequalities.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Beatriz Grinsztejn
- Telefonnummer: +55 2138659128
- E-Mail: beatriz.grinsztejn@gmail.com
Studienorte
-
-
Rio de Janeiro
-
Nova Iguaçu, Rio de Janeiro, Brasilien, 26030-380
- Rekrutierung
- Hospital Geral de Nova Iguaçu
-
Kontakt:
- José Henrique Pilotto, PhD
- E-Mail: pilotto@uninet.com.br
-
Rio de Janeiro, Rio de Janeiro, Brasilien, 21040360
- Rekrutierung
- Instituto Nacional de Infectologia Evandro Chagas
-
Kontakt:
- Emilia Jalil, PhD
- Telefonnummer: 55 2138659128
- E-Mail: emiliajalil@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Individuals aged 15 years or older
- Gay, bisexual, and other men who have sex with men (MSM)
- Transgender women and travestis
- Other sexual and gender minorities (SGM)
- Cisgender women in situations of social or economic vulnerability
- Sex workers
- Individuals seeking HIV testing and/or pre-exposure prophylaxis (PrEP)
- HIV-negative at screening
- Willing and interested in initiating PrEP
- Eligible for PrEP according to Brazilian national guidelines
Exclusion Criteria:
- Positive HIV test result at screening or during study participation
- Individuals not eligible for PrEP according to Brazilian national guidelines
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Community-Based PrEP Delivery
Participants will receive HIV prevention services through a community-based delivery model, including HIV testing, counseling, and initiation of daily oral pre-exposure prophylaxis (PrEP) according to national guidelines.
Services will be provided in non-traditional settings, such as non-governmental organizations and mobile health units, with additional support through telehealth and mobile health (mHealth) strategies to enhance engagement, adherence, and retention in care.
Participants diagnosed with HIV during screening or follow-up will be referred for treatment within the public health system.
|
Participants will receive daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in accordance with Brazilian national guidelines for HIV prevention.
PrEP will be offered to eligible individuals who test HIV-negative at enrollment and during follow-up, with clinical monitoring and counseling provided as part of routine care.
Participants will receive HIV prevention services through community-based delivery strategies designed to reduce barriers to access.
These include provision of services in non-traditional settings such as non-governmental organizations and mobile health units, with on-site HIV testing, counseling, and same-day PrEP initiation by trained healthcare staff.
Participants will have access to telehealth consultations and mobile health (mHealth) interventions to support engagement in care, adherence to PrEP, and retention in follow-up.
These strategies may include remote clinical support, digital communication tools, and tailored adherence support interventions.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Feasibility of Community-Based PrEP Delivery
Zeitfenster: Up to 12 months
|
Feasibility will be assessed by the proportion of planned community-based PrEP service delivery activities successfully implemented.
Indicators will include: (1) number of community-based sites activated, (2) number of individuals screened for HIV, and (3) number of participants initiating PrEP.
Results will be summarized using counts and proportions.
|
Up to 12 months
|
|
Acceptability of Community-Based PrEP Delivery
Zeitfenster: Up to 12 months
|
Acceptability will be assessed using participant-reported outcomes collected through a structured acceptability questionnaire with Likert-scale items.
Scores will range from 1 to 5, with higher scores indicating greater acceptability of the intervention.
|
Up to 12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PrEP Uptake
Zeitfenster: Up to 12 months
|
Proportion of eligible participants who initiate PrEP after HIV testing and counseling in community-based settings.
|
Up to 12 months
|
|
PrEP Persistence (Retention in PrEP Care)
Zeitfenster: Up to 12 months
|
Proportion of participants who remain engaged in PrEP care over time, including continued use of PrEP and attendance at follow-up visits.
|
Up to 12 months
|
|
HIV Incidence
Zeitfenster: Up to 12 months
|
Number of new HIV infections diagnosed among study participants during the follow-up period.
|
Up to 12 months
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Durch Blut übertragene Infektionen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des Immunsystems
- Infektionen
- RNA-Virusinfektionen
- Viruserkrankungen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- HIV-Infektionen
- Verwaltung des Gesundheitswesens
- Lieferung der Gesundheitsversorgung
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Nukleinsäuren, Nukleotide und Nukleoside
- Öffentliche Gesundheit
- Umwelt und öffentliche Gesundheit
- Purines
- Desoxycytidin
- Cytidin
- Pyrimidin -Nucleoside
- Pyrimidine
- Gesundheitsdienste
- Belegschaft und Dienstleistungen für Gesundheitseinrichtungen
- Präventive Gesundheitsdienste
- Organophosphorverbindungen
- Nukleoside
- Desoxyribonukleoside
- Organophosphonate
- Adenin
- Öffentliche Gesundheitspraxis
- Patientenversorgung Management
- Primärprävention
- Tenofovir
- Emtricitabin
- Telemedizin
- Voraussetzungsprophylaxe
Andere Studien-ID-Nummern
- 84111624.4.1001.5262
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Jianfeng XieRekrutierungCLABSI – Central Line Associated Bloodstream InfectionChina
-
Assiut UniversityNoch keine RekrutierungCLABSI – Central Line Associated Bloodstream Infection | Peripher eingeführter Zentralkatheter | Nabelschnur venöser Katheter
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
University of MalayaTeleflexAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
Johns Hopkins UniversityBeendetCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
Klinische Studien zur Oral Pre-Exposure Prophylaxis (PrEP) (Tenofovir Disoproxil Fumarate/Emtricitabine)
-
Henry Ford Health SystemMerck Sharp & Dohme LLCAbgeschlossenMenschlicher ImmunschwächevirusVereinigte Staaten
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterAbgeschlossen
-
Emory UniversityCenters for Disease Control and PreventionAbgeschlossenHIV-InfektionenVereinigte Staaten
-
ANRS, Emerging Infectious DiseasesRekrutierung
-
University of Colorado, DenverAbgeschlossenGesunde Freiwillige | Pharmakokinetik
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterAbgeschlossenHIV infektionVereinigte Staaten
-
Gilead SciencesRekrutierungHIV-InfektionenVereinigte Staaten
-
University of Missouri-ColumbiaZurückgezogenUnfruchtbarkeit | HIVVereinigte Staaten
-
Gilead SciencesAbgeschlossenHIV-InfektionenVereinigte Staaten
-
University of WashingtonBill and Melinda Gates FoundationAbgeschlossen